Psilocybin could be the future of mental health care, with promising findings emerging from Australia’s first research trial using psychedelics to treat depression, led by Swinburne University of Technology.

The study found that by the end of twelve weeks of treatment, with two 25mg psilocybin sessions alongside other therapy supports, most participants experienced a “clinically meaningful reduction in depression symptoms”.

Lead researcher Swinburne’s Professor Susan Rossell says the trial offers hope to the millions of Australians struggling with depressive disorders, particularly those who are unresponsive to existing treatments.

“We found that psilocybin-assisted psychotherapy is an effective real-world treatment regimen for those with treatment-resistant depression.

“We’re making a substantial difference to people’s lives who may have run out of treatment options and hope, and putting Australia at the forefront of psychedelics research globally.”

The study evaluated the feasibility, safety, and efficacy of psilocybin with psychotherapeutic support for treatment-resistant depression. It also investigated predictors of treatment outcomes and individual variability in responses.

Factors such as participant mindset prior to dosing, having a spiritual experience during the session, or changing mindsets were identified as predictors of treatment success. On the contrary, treatment expectations were not a reliable predictor.

And though not all participants experienced substantial improvement, they did not experience any serious adverse effects, a finding that aligns with previous research.

“We’re exceptionally pleased with these promising early findings that pave the way for future psychedelic research on range of other mental health conditions,” says Professor Rossell.

“Depression is a debilitating condition, and this research could have a real impact on countless lives – not just sufferers but their loved ones. We look forward to continuing this lifesaving work.”